Healthier Communities Progress on CSL’s Access and Affordability Commitments Progress Focus area Commitment by FY2030 FY2026 FY2025 World Federation of Hemophilia (WFH), Humanitarian Aid Program 2,100 people with bleeding disorders treated 1,9931 1,8451 Improving access for anaemia treatment with FERINJECT® 450,000 people with anaemia treated in at least three low- and middle-income countries 207,0002 n/a3 1. Data is based on a calendar year and is a cumulative total of people on prophylaxis treatment since 2023, when CSL Behring commenced its commitment of donating a total of 500 million international units (IUs) of coagulation factor therapy over five years to the WFH as part of its continued support of the Humanitarian Aid Program. 2. This includes reduced pricing initiatives, treatment cost reductions and infusion cost coverage. Patient numbers are calculated based on periodic safety update report methodology of one patient per year needing 1350 mg of iron for treatment. 3. This commitment was announced at the end of FY2025; no comparative information is available. CSL understands that enabling healthier communities through focused positive impact benefits all: everyone deserves the opportunity to achieve and maintain their highest level of health and wellbeing. Outlined below and in the following pages are some examples of how CSL is helping to help create healthier communities. Access and affordability CSL is committed to improving patient outcomes and advancing global health through the development, manufacture and supply of innovative biotherapies and vaccines, helping address serious and life-threatening conditions, supporting longer, healthier lives and healthier communities. CSL facilitates access to essential, life-saving therapies, including vaccines, iron therapies, and plasma-derived and recombinant protein-based medicines, through a scalable global footprint. This network enhances product availability, particularly in underserved and vulnerable populations, and supports capacity building and knowledge sharing across healthcare systems globally. The Company works collaboratively with governments, payers and healthcare stakeholders to enable sustainable healthcare delivery. This includes advancing access and reimbursement approaches that reflect therapeutic value for individual patients, supporting timely regulatory approvals, and facilitating efficient market entry to reduce delays in patient access. CSL maintains ongoing engagement with policymakers, patient advocacy organisations and other stakeholders to inform its understanding and ability to respond to access barriers, evolving healthcare needs and public health priorities. CSL also contributes to equitable access through patient assistance programs, financial support initiatives and product donations, alongside targeted advocacy to improve affordability and access to care worldwide. US$22.32m Supporting product access across the world* US$15.0b Economic value distributed* * Limited assurance by Deloitte. 26 Healthier World
RkJQdWJsaXNoZXIy MjE2NDg3